Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on May 17, 2021. The filing serves to announce financial results and provide a business update for the quarter ended March 31, 2021. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Cincinnati, OH.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only indicates that a business update and financial results were announced.
Guidance, Outlook, and Risks
Management provided a business update alongside the financial results, but the specific content of the outlook, guidance, risks, or contingencies is not detailed in the Form 8-K text itself. The filing explicitly states that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, limiting its incorporation by reference.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release) referenced in this filing.
- Confirm the company name is Aerpio Pharmaceuticals, Inc. (Ticker: ARPO), as the metadata input incorrectly listed Whitehawk Therapeutics, Inc.
- Review the "business update" details in the press release for any changes in clinical trial status or strategic direction.
- Check the company's status as an emerging growth company and any election regarding extended transition periods for accounting standards.